Tech Company Financing Transactions
NephroDI Therapeutics Funding Round
NephroDI Therapeutics closed a Seed funding round on 5/13/2021. Investors included Xontogeny.
Transaction Overview
Company Name
Announced On
5/13/2021
Transaction Type
Venture Equity
Amount
Unknown
Round
Seed
Investors
Xontogeny (Chris Garabedian)
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1606 Chestnut St. 3
Philadelphia, PA 19103
USA
Philadelphia, PA 19103
USA
Phone
Undisclosed
Website
Email Address
Overview
NephroDI Therapeutics is developing a novel AMPK activator as a first-in-class potential therapy for Nephrogenic Diabetes Insipidus (NDI). The genesis of this technology began with Drs. Jeff Sands and Janet Klein, recognized clinical and research leaders in kidney diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Rachael Hagan
Founder
Ish Khanna
Founder
Janet Klein
Founder
Ram Pillarisetti
Founder
Jeffrey Sands
Browse more venture capital transactions:
Prev: 5/13/2021: Sanlo venture capital transaction
Next: 5/13/2021: Jellysmack venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to document every notable VC transaction. VC transactions on this site are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs